Table 1

Clinicopathological and immunohistochemical parameters in relation to LSD1 immunoreactivity in invasive ductal breast carcinoma
Variable Categorisation LSD1 immunoreactivity
n analysable low b abundant b p c
Clinicopathological data:
Tumour stagea
Tumour stagea 22 5 17 0.370
 pT2 5 2 3
 pT3 1 0 1
 pT4 1 1 0
 unknown 3
Lymph node statusa
 pN0 16 1 15 0.010
 pN1-3 9 5 4
 unknown 7
Histological grade
 G1 2 0 2 0.010
 G2 16 1 15
 G3 14 7 7
Histological type
 ductal 32
Immunohistochemistry (IHC):
Oestrogen receptor status
 negative (IRS 0–2) 10 6 4 0.004
 positive (IRS 3–12) 22 2 20
Progesterone receptor status
 negative (IRS 0–2) 14 6 8 0.090
 positive (IRS 3–12) 18 2 16
HER2 status
 weak (0-2+) 26 7 19 1.0
 strong (3+) 6 1 5

aAccording to UICC: TNM Classification of Malignant Tumours (7th edition). Sobin LH, Gospodarowicz MK, Wittekind CH (eds) Wiley-Blackwell, Oxford 2009.

bLSD1 immunoreactivity: low = IRS 0–9, abundant = IRS 10–12.

cFisher’s exact test (two-sided), bold face representing significant data (P <0.05).

Serce et al.

Serce et al. BMC Clinical Pathology 2012 12:13   doi:10.1186/1472-6890-12-13

Open Data